| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anesthesiology and Pain Management, University Health Network, Toronto General Hospital, and the University of Toronto, Toronto, Ontario, Canada.
Address correspondence to: Dr. Finola Naughton, Department of Anesthesia and Pain Management, University Health Network, Toronto General Hospital, 3 Eaton North 3-464, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada. E-mail: finola.naughton{at}uhn.on.ca
Purpose: To assess the effect of N-acetylcysteine (NAC) on acute renal failure and important clinical outcomes after cardiac surgery.
Methods: Two reviewers performed literature searches, using EMBASE and PubMed, of randomized controlled trials investigating the renoprotective effect of N-acetylcysteine in cardiac surgery. Treatment effects were calculated as relative risks (RR) with 95% confidence intervals (CI). Heterogeneity and publication bias were assessed using the I2 test and funnel plots, respectively. Meta regression was performed to assess the effect of baseline renal function and the use of aprotinin on renal function.
Results: Seven randomized controlled trials (RCTs) (n = 1000) were identified. No study could demonstrate, either independently or meta-analytically, an improvement in the postoperative increase in creatinine, mortality (RR 0.93, 95% CI 0.4 to 2.07), renal failure requiring renal replacement therapy (RR 1.01, 95% CI 0.49 to 2.12), myocardial infarction (RR 0.88, 95% CI 0.36 to 1.88), atrial fibrillation (RR 0.88, 95% CI 0.70 to 1.10), or stroke (RR 0.69, 95% CI 0.27 to 1.69). There was a small, though significant increase in postoperative blood loss among patients treated with NAC (weighted mean difference 119 mL 95% CI 51, 187). After meta regression neither increase in postoperative creatinine (r2 = 0.33) nor renal replacement therapy (r2 = 0.04) was associated with the baseline creatinine or with NAC dose (r2 =0.04).
Conclusion: This analysis did not find that treatment with NAC was associated with clinical renal protection during cardiac surgery, or improvement in other clinical outcomes.
1 Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J.I ndependent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104: 343–8.[Medline]
2 Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999; 14: 1158–62.
3 Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1: 19–32.
4 Zanardo G, Michielon P, Paccagnella A, et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg 1994; 107: 1489–95.
5 Abel RM, Buckley MJ, Austen WG, Barnett GO, Beck CH Jr, Fischer JE. Etiology, incidence, and prognosis of renal failure following cardiac operations. Results of a prospective analysis of 500 consecutive patients. J Thorac Cardiovasc Surg 1976; 71: 323–33.[Abstract]
6 Andersson LG, Ekroth R, Bratteby LE, Hallhagen S, Wesslen O. Acute renal failure after coronary surgery--a study of incidence and risk factors in 2009 consecutive patients. Thorac Cardiovasc Surg 1993; 41: 237–41.[Medline]
7 Antunes PE, Prieto D, Ferrao de Oliveira J, Antunes MJ. Renal dysfunction after myocardial revascularization. Eur J Cardiothorac Surg 2004; 25: 597–604.
8 Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg 1989; 98: 1107–12.[Abstract]
9 Del Duca D, Iqbal S, Rahme E, Goldberg P, de Varennes B. Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors. Ann Thorac Surg 2007; 84: 1264–71.
10 Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194–203.
11 Mangos GJ, Brown MA, Chan WY, Horton D, Trew P, Whitworth JA. Acute renal failure following cardiac surgery: incidence, outcomes and risk factors. Aust N Z J Med 1995; 25: 284–9.[Medline]
12 Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 968–72.
13 Chukwuemeka A, Weisel A, Maganti M, et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis. Ann Thorac Surg 2005; 80: 2148–53.
14 Grayson AD, Khater M, Jackson M, Fox MA. Valvular heart operation is an independent risk factor for acute renal failure. Ann Thorac Surg 2003; 75: 1829–35.
15 Kulka PJ, Tryba M, Zenz M. Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Crit Care Med 1996; 24: 947–52.[Medline]
16 Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139–43.[Medline]
17 Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510–24.
18 Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284–91.
19 Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005; 111: 3230–5.
20 Landoni G, Biondi-Zoccai GG, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008; 22: 27–33.[Medline]
21 Cogliati AA, Vellutini R, Nardini A, et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth 2007; 21: 847–50.[Medline]
22 Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004; 78: 1332–7; discussion 1337–8.
23 Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11: 97–104.
24 Vargas Hein O, Staegemann M, Wagner D, et al. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren Fail 2005; 27: 385–92.[Medline]
25 Lombardi R, Ferreiro A, Servetto C. Renal function after cardiac surgery: adverse effect of furosemide. Ren Fail 2003; 25: 775–86.[Medline]
26 Hummel M, Kuhn M, Bub A, et al. Urodilatin, a new therapy to prevent kidney failure after heart transplantation. J Heart Lung Transplant 1993; 12: 209–17; discussion 217–8.[Medline]
27 Brenner P, Meyer M, Reichenspurner H, et al. Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. Eur J Med Res 1995; 1: 137–43.[Medline]
28 Amano J, Suzuki A, Sunamori M, Tofukuji M. Effect of calcium antagonist diltiazem on renal function in open heart surgery. Chest 1995; 107: 1260–5.[Medline]
29 Bergman AS, Odar-Cederlof I, Westman L, Bjellerup P, Hoglund P, Ohqvist G. Diltiazem infusion for renal protection in cardiac surgical patients with preexisting renal dysfunction. J Cardiothorac Vasc Anesth 2002; 16: 294–9.[Medline]
30 Kawamura T, Nara N, Kadosaki M, Inada K, Endo S. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med 2000; 28: 2201–8.[Medline]
31 Morgera S, Woydt R, Kern H, et al. Low-dose prostacyclin preserves renal function in high-risk patients after coronary bypass surgery. Crit Care Med 2002; 30: 107–12.[Medline]
32 Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int 1988; 33: 1078–83.[Medline]
33 Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195: 17–22.
34 Kramer BK, Preuner J, Ebenburger A, et al.L ack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant 2002; 17: 910–5.
35 Bronicki RA, Backer CL, Baden HP, Mavroudis C, Crawford SE, Green TP. Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2000; 69: 1490–5.
36 Loef BG, Henning RH, Epema AH, et al. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2004; 93: 793–8.
37 Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest 2005; 128: 2677–87.[Medline]
38 Mandke A, Mevada H, Borkar S, Mandke N. Clinical efficacy of clonidine as an adjunct to anaesthesia for coronary artery bypass graft surgery. Ann Card Anaesth 1999; 2: 22–7.
39 Kaya K, Oguz M, Akar AR, et al. The effect of sodium nitroprusside infusion on renal function during reperfusion period in patients undergoing coronary artery bypass grafting: a prospective randomized clinical trial. Eur J Cardiothorac Surg 2007; 31: 290–7.
40 Burns KE, Chu MW, Novick RJ, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294: 342–50.
41 Ristikankare A, Kuitunen T, Kuitunen A, et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006; 97: 611–6.
42 El-Hamamsy I, Stevens LM, Carrier M, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007; 133: 7–12.
43 Haase M, Haase-Fielitz A, Bagshaw SM, et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007; 35: 1324–31.[Medline]
44 Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anesth 2007; 54: 872–81.
45 Sisillo E, Ceriani R, Bortone F, et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 2008; 36: 81–6.
46 Moss M, Wellman DA, Cotsonis GA. An appraisal of multivariable logistic models in the pulmonary and critical care literature. Chest 2003; 123: 923–8.[Medline]
47 Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med 2008; 36: 1427–35.
48 Wijeysundera DN, Rao V, Beattie WS, Ivanov J, Karkouti K. Evaluating surrogate measures of renal dysfunction after cardiac surgery. Anesth Analg 2003; 96: 1265–73.
49 Charlson ME, MacKenzie CR, Gold JP, Shires GT. Postoperative changes in serum creatinine. When do they occur and how much is important? Ann Surg 1989; 209: 328–33.[Medline]
50 Wijeysundera DN, Karkouti K, Dupuis JY, et al. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. JAMA 2007; 297: 1801–9.
51 Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Trovati M. N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. Eur J Clin Invest 2001; 31: 452–61.[Medline]
52 Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703–8.[Medline]
53 Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353–65.
54 Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471–9.
55 Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327–38.[Medline]
56 Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801–13.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
